Forward-Looking StatementsExcept for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve risks and uncertainties that may cause the Company’s actual results and financial condition currently from those currently expected be forward-looking statements. These risks and uncertainties are described in the Company’s filings with the Securities Act of 1933 and the Securities Exchange Act of 1934 set include the Risk Factors and elsewhere, and include, but are not limited to: dependence on the success of the Sanctura , Sanctura XR , Nebido , VANTAS and SUPPRELIN LA, the early stage of products under development, uncertainties related to clinical trials, regulatory approval and commercialization of our products, in particular, Sanctura XR, Nebido, VANTAS , SUPPRELIN LA and Valstar , risks associated with contractual agreements, the risk thatlarly for the manufacture and co-promotion of Sanctura and Sanctura XR and the manufacture of Nebido, VANTAS and Valstar connected, dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing and clinical trials, competition, additional funds and corporate partners, including for the development of our products, acquire failure and develop additional product candidates, changes in reimbursement policies and / or rates for Sanctura, DELATESTRYL and future products, history of operating losses and expectation of future losses, product liability and insurance uncertainties, risks associated with the Redux – related litigation, the risk that the businesses of Indevus and Valera Pharmaceuticals will not be integrated successfully in the period following the related merger, the risk that the cost savings and any other synergies from the merger may not be fully realized or may take longer than expected, market acceptance for the merger and approved products; risks of regulatory review and clinical trials; disruption from the transaction makes the relationships with customers, employees and suppliers affect; competition and its effect on pricing, spending, third-party relationships and revenues; dependence on intellectual property and a limited patents and rights, dependence on market exclusivity, valuation of our common stock, risks related to the repayment of debt, risks associated with increased leverage, general worldwide economic conditions and related uncertainties, the effect of changes in governmental regulations and other risks.
About NebidoNebido is a long-acting depot preparation of testosterone undecanoate in development for the treatment of male hypogonadism. Nebido is expected. The first three months of testosterone product in the U.S. In the growing market for testosterone replacement therapies Indevus acquired U.S. Rights to Nebido with Bayer Schering Pharma AG, Germany in July 2005.The carefully carefully and performance on the nature of stigmatization, coding that the participants experienced most commonly as approximately nurses. Categories include:.